SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to ...

The market size of the progressive supranuclear palsy treatment market is expected to experience significant growth in the coming years, as more research is conducted on the disease and new treatments ...

- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...

The progressive supranuclear palsy market is expected to witness steady growth due to increasing disease awareness, advancements in diagnostic tools, and ongoing clinical research focused on ...

On September 22, GemVax & KAEL announced that it has applied for the U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for 'GV1001,' its treatment for progressive supranuclear ...

The FDA has granted Orphan Drug designation to RT001 (Retrotope) for the treatment of progressive supranuclear palsy (PSP). The Food and Drug Administration (FDA) has granted Orphan Drug designation ...

On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive Supranuclear Palsy Research and Treatment Center" at Bundang Seoul National ...

Progressive supranuclear palsy (PSP) is a rare brain disorder that affects approximately 6 in 100,000 people worldwide. It causes muscle weakness and affects gait, balance and overall movement, as ...

The progressive supranuclear palsy market size shall grow significantly during the forecast period (2023–2032). This increase will be due to rising disease awareness and improving diagnosis, besides ...